The European Commission – DG Competition cleared with conditions an acquisition by AbbVie Inc. of Allergan Plc. in the markets for (i) post-conventional treatments for UC and CD, including all biologics and innovative small molecules, (ii) post-conventional treatments for UC and/or CD excluding anti-TNFs and (iii) IL-23 inhibitors for UC and CD.